Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ERNA - Ernexa Therapeutics Inc. So'nggi... | Finranks

Home

ERNA

E

Ernexa Therapeutics Inc. (ERNA)

NCM – Real vaqt narxi. Valyuta: USD

0.20

-0.01 (-2.98%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

0.20

+0.00 (0.50%)

Bozordan keyin: Mar 27, 2026, 7:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Videolar

No Data

There is no data to display

Press-relizlar

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant.

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Access the “What This Means” segment here

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO).